Lapatinib price in India
The Lapatinib 250mg tablet is used in the treatment of breast cancer. It is possible to stop or slow down the growth of cancer cells. It is either used alone or in combination with some other medicine to cure advanced-stage breast cancer.
Lapatinib 250mg tablet should be taken on an empty stomach, an hour before or two hours after a meal. The dose and duration vary according to the severity of your condition and your response to treatment.
Take it exactly as prescribed to avoid serious side effects. It may take several weeks or months for you to see or feel the benefits, but do not stop taking it unless your doctor tells you to.
Lapatinib tablet benefits
Breast cancer
Lapatinib 250mg Tablet is used to treat breast cancer and can be used alone or in combination with other medications or treatment methods such as chemotherapy. It relieves breast cancer symptoms such as breast lumps, bloody discharge from nipples, and changes in the shape or texture of the breast.
Lapatinib 250mg Tablet kills or slows the growth of cancer cells while also preventing cancer cell multiplication. If any of the side effects bother you, talk to your doctor.
References:
- GlaxoSmithKline, US Food & Drug Administration, [Accessed on 24th Jul 2021], https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022059s007lbl.pdf
- Novartis Pharmaceuticals UK Ltd., Electronic Medicines Compendium (EMC), [Revised on Oct 2020] [Accessed on 21st Jul 2021], https://www.medicines.org.uk/emc/files/pil.6292.pdf
Lapatinib 250mg uses
- Breast cancer
How to use Lapatinib 250mg tablet
Take this medication in the dose and for the duration prescribed by your doctor. Take it all at once. It should not be chewed, crushed, or broken. Lapatinib 250mg Tablet should be taken on an empty stomach.
How Lapatinib 250mg tablet works
Lapatinib 250mg Tablet works against the HER2 (human epidermal growth factor receptor protein) and EGFR (epidermal growth factor receptor) receptors, which are responsible for cell proliferation. This is how it inhibits cancer cell growth by activating downstream signalling pathways.
Lapatinib tablet side effects
Lapatinib tablet side effects may include severe diarrhoea, so drink plenty of fluids or consult your doctor if this bothers you. While taking this medication, you may be asked to have your blood pressure checked on a regular basis. Notify your doctor if you experience a severe headache, confusion, vision problems, nausea, or vomiting. Your doctor may examine your liver function before, during, and after taking this medication.
If you have liver or kidney problems, consult with your doctor before taking Lapatinib 250mg Tablet. Many other medications can interact with or be affected by this medication, so inform your healthcare team about all medications you are taking.
This medication should not be used during pregnancy or while breastfeeding. To avoid pregnancy, both males and females must use effective contraception during treatment.
Lapatinib tablet common side effects
- Abdominal pain
- Back pain
- Breathing problems
- Constipation
- Cough
- Diarrhea
- Fatigue
- Headache
- Hot flashes
- Increased bilirubin in the blood
- Insomnia (difficulty in sleeping)
- Joint pain
- Liver damage
- Loss of appetite
- Mucosal inflammation
- Nausea
- Pain in extremities
- Rash
- Stomatitis (Inflammation of the mouth)
- Vomiting
- Weakness
- Weight gain
Lapatinib 250mg Brands in India
| Product | Company | Price |
|---|---|---|
| Hertab | Hetero | INR 4000/Bottle | Buy Now |
| Tykerb 250mg Tablet | Novartis | INR 12800/Bottle | Buy Now |
| Hertinib | Adley | INR 4000/Bottle | Buy Now |
| Abnib | Abbott | INR 7900/Bottle | Buy Now |
| Libset | Intas | INR 5000/Bottle | Buy Now |
| Cadilap | Cadial | INR 4000/Bottle | Buy Now |
| Tylidys | Zydus Capida | INR 6000/Bottle | Buy Now |
| Etibo | Smarth | INR 4500/Strip | Buy Now |
| Herlapsa | Mylan | INR 5000/Bottle | Buy Now |
| Combinib | Cipla | INR 5500/Bottle | Buy Now |
FAQ - Lapatinib
Lapatinib belongs to a class of drugs known as kinase inhibitors. It works by preventing the abnormal protein from signalling cancer cells to multiply. This slows or stops the spread of cancer cells.
Lapatinib mechanism of action is action is the inhibition of tyrosine kinase phosphorylation, which dampens and/or stops signal transduction along the PI3K/Akt and ras/raf/MAPK pathways.
- nausea.
- vomiting.
- heartburn.
- sores on the lips, mouth, or throat.
- loss of appetite.
- red, painful, numb, or tingling hands and feet.
- dry skin.
- pain in the arms, legs, or back.
Lapatinib, a tyrosine kinase inhibitor that suppresses the epidermal growth factor receptor and ErbB2, has been used in the treatment of advanced or metastatic breast cancer. According to reports, lapatinib has caused cardiovascular side effects such as QT-interval prolongation and heart failure.
Lapatinib ditosylate monohydrate, equivalent to 250 mg lapatinib, is contained in each film-coated tablet.
Lapatinib is marketed under the brand name TYKERB. In some cases, health care professionals may refer to the generic drug name lapatinib by the trade name TYKERB. Like Hertab, Hertinib, Abnib, Libset, Cadilap, Tylidys, Etibo, Herlapsa, Combinib, etc.
Lapatinib is used in combination with capecitabine (Xeloda) to treat a specific type of advanced breast cancer in patients who have already received other chemotherapy medications.
Breast Cancer
HER2-overexpressing metastatic breast cancer
- indicated in combination with capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumours overexpress HER2 and who have received prior therapy including an anthracycline, a taxane, and trastuzumab.
- 1250 mg PO qDay on Days 1-21 in a repeating 21-day cycle, in combination with capecitabine (2000 mg/m2/day PO divided q12 hr) on Days 1-14.
Hormone-positive and HER2-positive advanced breast cancer
- Indicated in combination therapy with letrozole for the treatment of postmenopausal women with hormone receptor-positive and HER2-positive breast cancer, for whom hormonal therapy is indicated
- 1500 mg PO qDay given continuously in conjunction with 2.5 mg PO qDay letrozole
Lapatinib is a targeted therapy. Lapatinib is classified as a signal transduction inhibitor (tyrosine kinase inhibitor, inhibitor of EGFR and HER2).
Tykerb lapatinib, used in the form of lapatinib ditosylate, is an orally active drug for breast cancer and other solid tumors. It is a dual tyrosine kinase inhibitor that interrupts the HER2/neu and epidermal growth factor receptor pathways. It is used in combination therapy for HER2-positive breast cancer.
INR 12800